Company news

Vivani Medical, Inc. news in 2025

Vivani Medical, Inc.'s news releases, calls and decks from 2025, newest first.

View company

Vivani Medical Provides Business Update and Reports Third Quarter 2025 Financial Results

November 13, 2025

Vivani Medical to Present at the ThinkEquity Conference on October 30, 2025

October 22, 2025

Vivani Medical Withdraws Record Date for Cortigent Neuromodulation Subsidiary Spin-Off

October 3, 2025

Vivani Medical to Present at the Emerging Growth Conference on September 25, 2025

September 24, 2025

Vivani Medical Announces Record Date for Spin-off of Cortigent Neuromodulation Subsidiary to Shareholders

September 17, 2025

Vivani Medical Provides Update on Clinical Development Plans for NPM-139 Semaglutide Implant for Chronic Weight Management

September 4, 2025

Vivani Medical CEO Adam Mendelsohn to Present at the H.C. Wainwright 27th Annual Global Investment Conference on September 10, 2025

August 20, 2025

Vivani Medical Provides Business Update Including $10M Equity Financing and Reports Second Quarter 2025 Financial Results

August 13, 2025

Vivani Medical Announces Rapid Advancement of NPM-139, a Novel Semaglutide Implant, Following Positive Weight Loss Data from an Ongoing Preclinical Study of NPM-139 and Promising Results from the LIBERATE-1 Phase 1 Clinical Study of NPM-115

August 5, 2025

Vivani Medical Appoints Anthony Baldor as Chief Financial Officer

June 11, 2025

Vivani Medical to Present at the 2025 BIO International Convention

June 10, 2025

Vivani Medical Announces Filing of Form 10 Registration Statement for Planned Spin-Off of Cortigent Neurostimulation Business to Vivani Shareholders

May 29, 2025

Vivani Medical Provides Business Update Including $3M Equity Financing and Reports First Quarter 2025 Financial Results

May 13, 2025

Vivani Medical to Present at the American Association of Pharmaceutical Scientists’ “Beyond GLP1s: Where the Science will Take Business Next” Virtual Workshop

May 7, 2025

Vivani Medical to Participate in Virtual Fireside Chat Hosted by H.C. Wainwright & Company

April 16, 2025

Vivani Medical and Okava Expand Collaboration to Develop OKV-119 for Dogs, Targeting Metabolic Health and Longevity

April 15, 2025

Vivani Medical Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

March 31, 2025

Vivani Medical Announces $8.25M Private Placement Equity Financing

March 27, 2025

Vivani Medical Announces Positive Preclinical Weight Loss Data for NPM-139 Semaglutide Implant, with Potential for Once-Yearly Dosing

March 26, 2025

Vivani Medical to Present at the Emerging Growth Conference on March 27, 2025

March 24, 2025

Vivani Medical Achieves First Implant and Full Enrollment in the First-in-Human Clinical Trial of GLP-1 Implant NPM-115 in Obese or Overweight Adults

March 13, 2025

Vivani Medical Announces Intent to Spin Off Cortigent Neurostimulation Business

March 12, 2025

Decks in 2025